Stocktoria
TherapeuticsMD, Inc. TXMD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2001-01-31
TherapeuticsMD, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | — | 100.0% | 98.0% | 45.5% |
| Operating margin | -145.3% | -347.1% | -654.6% | 1.7% | -3092.8% |
| Net margin | -18.8% | -123.9% | -789.4% | 160.1% | -6700.9% |
| FCF margin | — | — | — | — | -5547.1% |
| Return on assets | -1.5% | -5.6% | -23.7% | 123.8% | -101.7% |
| Return on equity | -2.1% | -8.0% | -35.1% | 318.7% | 184.2% |
| Debt / equity | — | — | — | — | -2.01× |
| Current ratio | 3.02 | 2.37 | 1.72 | 1.18 | 0.47 |
| Revenue growth | 71.6% | 35.3% | -98.1% | 2619.1% | -96.0% |
Source: SEC EDGAR filings · CIK 0000025743 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.